Results 191 to 200 of about 53,999 (225)
Some of the next articles are maybe not open access.
The biology and pathogenesis of vivax malaria
Trends in ParasitologyPlasmodium vivax contributes significantly to global malaria morbidity. Key advances include the discovery of pathways facilitating invasion by P. vivax merozoites of nascent reticulocytes, crucial for vaccine development. Humanized mouse models and hepatocyte culture systems have enhanced understanding of hypnozoite biology.
Nicholas M. Anstey +5 more
openaire +3 more sources
Vivax Malaria and Thrombocytopenia
Indian Journal of Public Health Research & Development, 2014Severe thrombocytopenia is common in isolated falciparum and mixed falciparum/vivax malaria and is rare in isolated P. vivax infection, but the trend is changing. We hereby report 14 cases of P. vivax with thrombocytopenia, with 8 cases requiring blood/blood product transfusions.
Ravinder Garg +6 more
openaire +1 more source
CURE OF CHRONIC VIVAX MALARIA WITH PENTAQUINE
Journal of the American Medical Association, 1949The treatment of malaria has been characterized by failure to obtain permanent cure in many cases, in spite of the fact that either quinine or quinacrine hydrochloride ("atabrinedi-hydrochloride") will afford prompt relief of the acute attack. Post-treatment recurrences or relapses occur in a high percentage of patients with vivax and quartan malaria ...
L T, COGGESHALL, F A, RICE
openaire +2 more sources
Vaccination for vivax malaria: targeting the invaders
Trends in Parasitology, 2004Among the surface-exposed antigens of the malaria parasite, those with known essential functions that can be disrupted by antibodies represent the most promising candidates for development as malaria vaccines. Two recombinant protein subunits of the Plasmodium vivax merozoite surface protein 1 have been shown to bind to reticulocytes in enzyme-linked ...
Spencer D, Polley +2 more
openaire +2 more sources
The immunology of Plasmodium vivax malaria
Immunological Reviews, 2019AbstractPlasmodium vivax infection, the predominant cause of malaria in Asia and Latin America, affects ~14 million individuals annually, with considerable adverse effects on wellbeing and socioeconomic development. A clinical hallmark of Plasmodium infection, the paroxysm, is driven by pyrogenic cytokines produced during the immune response.
Lis R. Antonelli +5 more
openaire +2 more sources
The neglected burden of Plasmodium vivax malaria
The American Journal of Tropical Medicine and Hygiene, 2001We estimate that the global burden of malaria due to Plasmodium vivax is approximately 70-80 million cases annually. Probably approximately 10-20% of the world's cases of P. vivax infection occur in Africa, south of the Sahara. In eastern and southern Africa, P.
K, Mendis +3 more
openaire +2 more sources
UNCOMMON CLINICAL MANIFESTATIONS OF VIVAX MALARIA
Journal of the American Medical Association, 1946The clinical diagnosis of vivax malaria in this country is often not difficult. The patient, in many instances, can suggest the correct diagnosis at the onset of an attack, and this can easily be confirmed by the demonstration of malarial parasites in one or more examinations of blood smears.
H, MOST, J M, HAYMAN
openaire +2 more sources
Speculations on the origins of Plasmodium vivax malaria
Trends in Parasitology, 2003It is likely that Plasmodium vivax diverged approximately 2 million years ago from a group of malaria parasites which are now endemic in monkeys and apes in southern Asia. In those times, primates were spread throughout most of Eurasia and Africa, indicating an Old World location, but nothing more precise, for the place of divergence of P. vivax.
openaire +2 more sources
THROMBOCYTOPENIA IN VIVAX MALARIA
The Lancet, 1964G J, HILL, V, KNIGHT, G M, JEFFERY
openaire +2 more sources